Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer

被引:39
作者
Holten-Andersen, Mads Nikolaj
Nielsen, Hans Jorgen
Sorensen, Steen
Jensen, Vibeke
Brunner, Nils
Christensen, Ib Jarle
机构
[1] Royal Vet & Agr Univ, Inst Vet Patobiol, DK-1870 Frederiksberg, Denmark
[2] Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark
[3] Hvidovre Univ Hosp, Dept Surg Gastroenterol, Copenhagen, Denmark
[4] Hvidovre Univ Hosp, Dept Clin Biochem, Copenhagen, Denmark
关键词
colorectal cancer; TIMP-1; follow-up; plasma; CEA;
D O I
10.1016/j.ejca.2006.01.058
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to investigate whether the pre- and postoperative plasma levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) were associated with outcome in colorectal cancer (CRC). Pre- and postoperative plasma TIMP-1 from 280 curatively resected CRC patients and carcinoembryonic antigen (CEA) in corresponding serum samples were measured and correlated with patient outcome (death, local recurrence (LR) and distant metastases (DM)). The results showed that the course of plasma TIMP-1 from pre- to postoperative levels correlated with patient outcome (P = 0.005). However, postoperative plasma TIMP-1 alone was strongly associated with patient outcome, high TIMP-1 predicting short survival (P = 0.002). Combining postoperative TIMP-1 and CEA demonstrated that high TIMP-1 and CEA levels predicted poor outcome (P < 0.0001); multivariate analysis identifying both parameters as strong prognostic factors for survival, LR and DM (P < 0.0001). In conclusion, postoperative plasma TIMP-1 predicts patient outcome both alone and in combination with CEA. Postoperative TIMP-1 may be a marker of residual disease after primary surgery for CRC.
引用
收藏
页码:1889 / 1896
页数:8
相关论文
共 30 条
[1]   SIMPLE PARAMETRIC AND NONPARAMETRIC MODELS FOR EXCESS AND RELATIVE MORTALITY [J].
ANDERSEN, PK ;
VAETH, M .
BIOMETRICS, 1989, 45 (02) :523-535
[2]  
BABSON AL, 1991, J CLIN IMMUNOASSAY, V14, P83
[3]   2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines [J].
Benson, AB ;
Desch, CE ;
Flynn, PJ ;
Krause, C ;
Loprinzi, CL ;
Minsky, BD ;
Petrelli, NJ ;
Pfister, DG ;
Smith, TJ ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3586-3588
[4]   Surveillance after colorectal cancer resection [J].
Berman, JM ;
Cheung, RJ ;
Weinberg, DS .
LANCET, 2000, 355 (9201) :395-399
[5]   MATRIX METALLOPROTEINASES - A REVIEW [J].
BIRKEDALHANSEN, H ;
MOORE, WGI ;
BODDEN, MK ;
WINDSOR, LJ ;
BIRKEDALHANSEN, B ;
DECARLO, A ;
ENGLER, JA .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250
[6]   IMMUNOASSAYS FOR THE DETECTION OF HUMAN COLLAGENASE, STROMELYSIN, TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP) AND ENZYME-INHIBITOR COMPLEXES [J].
COOKSLEY, S ;
HIPKISS, JB ;
TICKLE, SP ;
HOLMESIEVERS, E ;
DOCHERTY, AJP ;
MURPHY, G ;
LAWSON, ADG .
MATRIX, 1990, 10 (05) :285-291
[7]   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].
Cunningham, D ;
Pyrhönen, S ;
James, RD ;
Punt, CJA ;
Hickish, TF ;
Heikkila, R ;
Johannesen, TB ;
Starkhammar, H ;
Topham, CA ;
Awad, L ;
Jacques, C ;
Herait, P .
LANCET, 1998, 352 (9138) :1413-1418
[8]   SEQUENCE OF HUMAN-TISSUE INHIBITOR OF METALLOPROTEINASES AND ITS IDENTITY TO ERYTHROID-POTENTIATING ACTIVITY [J].
DOCHERTY, AJP ;
LYONS, A ;
SMITH, BJ ;
WRIGHT, EM ;
STEPHENS, PE ;
HARRIS, TJR ;
MURPHY, G ;
REYNOLDS, JJ .
NATURE, 1985, 318 (6041) :66-69
[9]   Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines [J].
Duffy, MJ ;
van Dalen, A ;
Haglund, C ;
Hansson, L ;
Klapdor, R ;
Lamerz, R ;
Nilsson, O ;
Sturgeon, C ;
Topolcan, O .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) :718-727
[10]   The classification of cancer of the rectum [J].
Dukes, CE .
JOURNAL OF PATHOLOGY AND BACTERIOLOGY, 1932, 35 (03) :323-332